 Anabolic Agents
"Anabolic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power.
| Descriptor ID |
D045930
|
| MeSH Number(s) |
D27.505.696.399.472.080
|
| Concept/Terms |
Anabolic Effect- Anabolic Effect
- Effect, Anabolic
- Anabolic Effects
- Effects, Anabolic
|
Below are MeSH descriptors whose meaning is more general than "Anabolic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anabolic Agents".
This graph shows the total number of publications written about "Anabolic Agents" by people in this website by year, and whether "Anabolic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anabolic Agents" by people in Profiles.
-
Neil D, Clark RV, Magee M, Billiard J, Chan A, Xue Z, Russell A. GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass in Healthy Older Men and Women. J Clin Endocrinol Metab. 2018 09 01; 103(9):3215-3224.
-
Beck DT, Yarrow JF, Beggs LA, Otzel DM, Ye F, Conover CF, Miller JR, Balaez A, Combs SM, Leeper AM, Williams AA, Lachacz SA, Zheng N, Wronski TJ, Borst SE. Influence of aromatase inhibition on the bone-protective effects of testosterone. J Bone Miner Res. 2014 Nov; 29(11):2405-13.
-
Jasuja R, Costello JC, Singh R, Gupta V, Spina CS, Toraldo G, Jang H, Li H, Serra C, Guo W, Chauhan P, Narula NS, Guarneri T, Ergun A, Travison TG, Collins JJ, Bhasin S. Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy. Aging Cell. 2014 Apr; 13(2):303-10.
-
McCoy SC, Yarrow JF, Conover CF, Borsa PA, Tillman MD, Conrad BP, Pingel JE, Wronski TJ, Johnson SE, Kristinsson HG, Ye F, Borst SE. 17?-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement. Bone. 2012 Oct; 51(4):667-73.
-
Minor BD, Heusinger DE, Melanson EL, Hamilton KL, Miller BF. Energy balance changes the anabolic effect of postexercise feeding in older individuals. J Gerontol A Biol Sci Med Sci. 2012 Nov; 67(11):1161-9.
-
Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA, Bukata SV, O'Keefe RJ, Awad H, Puzas JE, Rosier RN, Zuscik MJ. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med. 2011 Sep 21; 3(101):101ra93.
-
Yarrow JF, Conover CF, McCoy SC, Lipinska JA, Santillana CA, Hance JM, Cannady DF, VanPelt TD, Sanchez J, Conrad BP, Pingel JE, Wronski TJ, Borst SE. 17?-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab. 2011 Apr; 300(4):E650-60.
-
Finnoff JT, Chimes GP, Murray TH. Performance-enhancing drugs. PM R. 2010 Apr; 2(4):285-93.
-
Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010 Jun; 75(6):377-89.
-
Ipaktchi K, Arbabi S. Advances in burn critical care. Crit Care Med. 2006 Sep; 34(9 Suppl):S239-44.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|